Canadian label and evidence guide | Sources checked October 9, 2026 | No clinician review
Direct answer: A copper-peptide face serum and an injectable product advertised as GHK-Cu are not interchangeable. A cosmetic ingredient name, a notification number or a skincare study does not establish authorization or evidence for an injection. In Canada, assess the finished product, route and claims separately.
Copper peptides are discussed in cosmetic skincare, while GHK-Cu is also promoted online in injectable products. Those are not interchangeable contexts.
Route changes the risk
A topical cosmetic used on intact skin and an injected product enter the body differently, are manufactured under different expectations, and require different evidence. A discussion about cosmetic appearance cannot validate an injectable product.
Canadian status matters
Health Canada’s April 2026 warning named GHK-Cu among examples of unauthorized injectable peptide drugs sold online and advised consumers not to buy or use unauthorized injectable products.
The practical takeaway is simple: do not transfer reassurance from a face serum to a vial. Check the exact product, route, label, and authorization.
Source: Health Canada warning on unauthorized injectable peptide drugs.
Does a Cosmetic Number mean Health Canada approved the serum?
No. Health Canada explicitly says that processing a cosmetic notification and issuing a Cosmetic Number are not approval for sale, confirmation of compliance or agreement that the product qualifies as a cosmetic. The number is administrative. That distinction comes from the regulator’s cosmetic notification guidance, not an assessment of any particular brand.
A notification should therefore not be presented as a drug authorization or as proof that a serum produces a clinical benefit. Equally, a cosmetic does not become unauthorized simply because it does not carry a drug DIN. The applicable category depends on the actual product. Our Canadian peptide-skincare label guide explains that starting point.
Why do the words around the ingredient matter?
Health Canada’s cosmetic-drug classification guidance considers both composition and representation. Claims can be explicit or implied through packaging, images or advertising. Calling something a serum does not settle its category if its overall presentation promises a therapeutic effect.
A claim about the appearance of skin is a different question from a claim to treat a disease or heal an injury. If a product page moves between those meanings, the evidence and regulatory explanation should not move unnoticed with it. This article cannot classify an individual product or determine whether a company’s advertising complies with Canadian law. Those decisions require the exact formulation, claims and applicable regulatory assessment.
What can a Canadian cosmetic label actually tell you?
The Canadian cosmetic labelling requirements include an ingredient list using International Nomenclature of Cosmetic Ingredients, or INCI, product identity, contact information and applicable warnings. An ingredient list is useful for identifying what the label declares. It is not a report of the finished product’s clinical performance.
Read the exact ingredient wording rather than treating every copper-peptide marketing phrase as a synonym. Record the product name, ingredient list, intended use and the particular benefit being claimed. Without those details, a comparison can quietly switch from one formulation to another while retaining the same broad peptide language.
Is absence from the Cosmetic Ingredient Hotlist a safety endorsement?
No. Health Canada’s Hotlist explanation says the tool is not exhaustive and that the general safety obligations still apply. Its cosmetic-ingredient safety overview also cautions that absence from the list does not necessarily establish safety.
That means a search result showing no restriction is not enough to certify a finished serum, its claims or a different route of exposure. This guide does not report that every copper-peptide formula is compliant or that any particular product has passed a safety assessment.
How do you check whether a cited study answers the serum question?
Our editorial test is to match the study to the claim before discussing its result. These questions help keep the comparison specific:
- Was it a human study? A laboratory mechanism or an animal experiment is not a demonstration of a cosmetic outcome in people.
- Was the route the same? Topical, injected and other exposures must not be treated as one intervention.
- Was the finished formulation the same? Evidence about an isolated ingredient does not automatically test the product on a shelf.
- What was the comparator? A comparison with another formula or a vehicle can answer a different question from an uncontrolled before-and-after image.
- What changed, and for how long? A measured appearance outcome, a participant’s impression and a biological marker are not equivalent results.
- Who funded the work, and what is missing? Sponsorship, small samples, incomplete methods and limited follow-up belong in the interpretation.
These are evidence-reading questions, not a finding that GHK-Cu serums do or do not work. We have not tested a product, estimated a benefit or ranked brands here. For another example of keeping a cosmetic claim tied to the studied outcome, see our peptide eye-cream evidence guide.
Can a laboratory certificate bridge the gap to an injection?
No. Health Canada’s April 9, 2026 injectable-peptide advisory addresses unauthorized products and quality risks, including uncertainty about contents and sterile manufacturing. A document showing selected sample tests is not Canadian authorization for a finished injectable drug.
Our certificate-of-analysis checklist explains what those documents leave unanswered. It is not a sourcing checklist. The practical takeaway is to keep three questions separate: what the label says, what the relevant evidence studied and what the regulator authorized.
Scope, verification and further reading
This October 9 update expands the original route distinction with Canadian notification, labelling and classification context. The cited Health Canada pages were rechecked on that date. The injectable advisory remains an April advisory, not a new October warning. No individual serum, injectable preparation or seller has been assessed.
For molecule-specific Canadian regulatory reporting, see PeptideInfo.ca’s GHK-Cu route and authorization report. PeptideInfo.ca and PeptideCare.ca are companion publications under shared ownership. This page focuses on reading care and cosmetic claims; the companion covers regulatory records and research reporting.
Educational boundary: This is general information, not medical or legal advice, a product recommendation or clinician review. It provides no dosing, administration, purchasing, prescribing, clinic referral or personalized skincare plan.
Evidence companion: For molecule-specific evidence and Canadian authorization reporting, consult PeptideInfo.ca.
General education only. Source-based reporting, not individualized medical advice or clinician review.